| Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (NCT05319028) | Calithera Biosciences, Inc | 2022-06-23 |
| NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial (NCT04698681) | Calithera Biosciences, Inc | 2021-01-19 |
| Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects (NCT04607512) | Calithera Biosciences, Inc | 2020-10-05 |
| Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis (NCT04279769) | Calithera Biosciences, Inc | 2020-07-03 |
| A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors (NCT03965845) | Calithera Biosciences, Inc | 2019-06-25 |
| Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors (NCT03875313) | Calithera Biosciences, Inc | 2019-05-20 |
| A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL) (NCT03772288) | Calithera Biosciences, Inc | 2019-04-03 |
| A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies (NCT03338881) | Calithera Biosciences, Inc | 2018-05-10 |
| CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma (NCT03428217) | Calithera Biosciences, Inc | 2018-04-24 |
| A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor (NCT03359733) | Calithera Biosciences, Inc | 2018-02-28 |
| A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma (NCT03357627) | Calithera Biosciences, Inc | 2018-02-16 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies (NCT03370302) | Calithera Biosciences, Inc | 2018-01-17 |
| TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (NCT03123393) | Calithera Biosciences, Inc | 2017-10-10 |
| CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC) (NCT03163667) | Calithera Biosciences, Inc | 2017-09-06 |